A meta-analysis showed an overall incidence of all-grade colitis of 13.6% in patients treated with a combination therapy of ipilimumab/nivolumab, 9.1% in patients receiving ipilimumab, and 1.3% with anti-PD1/PD-L1 monotherapy [111]. Here, PDCD1 is linked to colitis.